微流体的传统与PEGylated加载脂肪体配方,用于提供水友性化疗
Eman Jaradat1, Adam Meziane2, Dimitrios A Lamprou1
1School of Pharmacy, Queen's University Belfast, 97 Lisburn Road, Belfast BT9 7BL, UK.
International journal of pharmaceutics
|April 3, 2024
概括
这项研究比较了传统和PEGylated脂质体用于Carboplatin的输送. 微流体增强了封装效率,PEGylated脂质体显示较小的尺寸和更好的稳定性,而传统的提供更好的均性.
科学领域:
- 纳米技术 纳米技术
- 材料科学 材料科学 材料科学
- 制药科学 制药科学
背景情况:
- 药物输送系统 (DDS) 对于改善癌症治疗至关重要,因为它可以将癌症药物向特定的器官,并最大限度地减少向健康组织的分配.
- 纳米粒子 (NP),特别是基于脂质的物质,如脂质体,是有效的DDS,因为其毒性低,并且能够携带多种分子.
- 由DPPC和胆固醇组成的脂质体被研究为化学疗法药物卡博普拉丁的载体.
研究的目的:
- 开发和比较传统的脂质体和PEGylated脂质体用于卡博白金的输送.
- 调查不同 DSPE-PEG2000 度对 PEGylated 脂质体特征 (直径,多分散性, ζ-潜力,封装效率,药物释放) 的影响.
- 评估水力动力学微流体系统在提高卡博普拉丁封装效率方面的有效性.
主要方法:
- 制造传统的脂质体 (DPPC,胆固醇) 和PEG化脂质体 (DPPC,胆固醇,DSPE-PEG2000).
- 在两种类型的脂质体中加载碳白金.
- 脂质体的特征包括NP直径,多分散性和z电位.
- 封装效率 (EE%) 和药物释放概况的评估.
- 利用水力动力微流体系统进行增强封装.
主要成果:
- 微流体系统表明,它有望提高卡博普拉丁封装效率.
- 与传统脂质体相比,PEG化脂质体的颗粒径更小,稳定性更好.
- 传统的脂质体显示出更好的同质性和更高的封装效率,用于水友性分子,如卡博白金.
结论:
- 脂质体是有效的纳米载体,用于在癌症治疗中输送碳酸.
- 基化改善了脂质体的稳定性和大小,而微流体可以提高封装效率.
- 常规和PEGylated脂质体之间的选择取决于特定的药物特性和所需的输送特征.
相关概念视频
Modified-Release Drug Delivery Systems: Rate-Programmed II
Rate-programmed drug delivery systems release drugs in a controlled manner to maintain therapeutic levels. Three main designs include reservoir, matrix, and hybrid systems.Reservoir systems consist of a drug core enclosed within a membrane that controls drug release. In non-swelling reservoir systems, polymers like ethyl cellulose or polymethacrylates are used. These do not hydrate in aqueous media and control release through membrane thickness, porosity, or insolubility. This type includes...
Modified-Release Drug Delivery Systems: Classification
Modified-release drug delivery systems improve drug efficacy and minimize side effects by controlling the rate and location of drug release. These systems fall into three categories: rate-programmed, stimuli-activated, and site-targeted.Rate-programmed systems release drugs at a predetermined rate, maintaining consistent therapeutic levels and reducing fluctuations that could lead to toxicity or subtherapeutic effects. These systems use polymeric matrices, reservoir-based designs, or osmotic...
Modified-Release Drug Delivery Systems: Rate-Programmed I
Rate-programmed drug delivery systems (DDS) are designed to release drugs at specific, controlled rates to maintain consistent therapeutic levels. These systems are categorized based on their release mechanisms, including dissolution-controlled DDS, diffusion-controlled DDS, and combined dissolution-diffusion-controlled DDS.In dissolution-controlled DDS, the release rate depends on the slow dissolution of the drug itself or the surrounding matrix. Drugs with inherently slow dissolution rates,...
Modified-Release Drug Delivery Systems: Site-Targeted
Site-targeted drug delivery systems enhance therapeutic efficacy while minimizing systemic toxicity and treatment costs. Unlike conventional methods, these systems ensure precise drug delivery, improving bioavailability and reducing side effects. Targeted drug delivery is classified into three levels. First-order targeting directs drugs to the capillary beds of specific organs or tissues. Second-order targets specific cell types, such as tumor cells, using receptor-mediated interactions.
Site-Targeted Drug Delivery Systems: Polymeric Carriers
Polymeric carriers enhance targeted drug delivery by increasing efficacy while minimizing off-target effects. These carriers comprise a biodegradable polymeric backbone integrated with functional elements that enable targeting, improve physicochemical properties, and regulate drug release.Targeting MechanismsThe targeting ability of polymeric carriers is mediated by a homing device, which is a molecular recognition component designed to selectively bind to specific tissues or cells. Monoclonal...
Oral Drug Delivery Systems: Continuous-Release Systems
Continuous-release drug delivery systems offer a strategic approach to maintaining therapeutic drug levels over extended periods following oral administration. By modulating the release rate of active pharmaceutical ingredients, these systems minimize fluctuations in plasma concentrations, which enhances clinical efficacy and reduces the need for frequent dosing. Such characteristics make them particularly advantageous in managing chronic diseases where patient adherence and stable drug...


